SANJEEV JAIN
-
Akums announces unaudited consolidated financial results for Q1 FY25
The company’s CDMO segment which accounts for 77 per cent of total revenue and 93 per cent of the Adj EBITDA, grew to Rs 7,820 million an increase of 5.6 per cent year-on-year (YoY). This was driven by strong growth in sales volume of 13.9 per cent. Segment EBITDA also saw margin expansion of 106 bps to 15.5 per cent, growing 13.4 per cent YoY to Rs 1,212 million on the back of steady improvement in capacity utilisation and better product mix.
-
Akums Drugs and Pharmaceuticals unveils nasal sprays
-
Akums launches Lasmiditan tablet to alleviate symptoms associated with migraine
-
Akums launches Doxylamine + Pyridoxine extended-release tablets
-
Keeping our seniors active and healthy is our top priority: Sanjeev Jain, Founder, NEMA Elder Care
-
Akums announces entry into nutraceutical gummies segment
-
Akums, Lyrus Life Sciences collaborate for patented technologies and formulations
-
Akums gets DCGI nod to launch anti-diabetic drug Lobeglitazone in India
-
Akums receives EU GMP approval for two manufacturing units in Haridwar
Advertisement
Advertisement